Fusarium head blight disease resistance. Field of the Invention

The current invention relates to resistance to Fusarium head blight disease. In particular, the invention relates to a gene contributing to resistance to Fusarium head blight disease and a recombinant construct including said gene. The invention also relates to plant cells transformed with the gene and plant material, including plant cell cultures, seeds and plants, comprising the transformed plant cells.

Background of the Invention Fusarium head blight (FHB) is a fungal disease in plants, in particular, in cereals such as wheat, barley and oats. It is caused by a Fusarium fungus, with the species Fusarium graminearum is the predominant causal agent of the disease in most areas of the world. In wheat, the fungus infects the head of the plant and causes the kernels to shrivel up. It can also produce a mycotoxin that further reduces the quality of kernel. These toxins can also be harmful to both animals and humans.

FHB in wheat is an economic presage and its post-harvest grain loss and considerable health risk to animals and humans due to accumulation of mycotoxin deoxynivalenol (DON), are well known. Given the economic concern of FHB, several control strategies have been developed to avert FHB epidemics. These include resistance cultivars and systems for the control of FHB and both chemical and biological control.

The use of host resistance is considered to be an efficacious means to control FHB in wheat and several approaches have been described previously. Breeding and selection of crossed lines for durable resistance to disease and yield stability take time and lines behave differently in different environments. There is also the chance of resistance breakdown in lines developed with this approach.

EBI accession no. EMBL: HP612298 describes a sequence from Triticum aestivum cultivar Bobwhite. EBI accession no. UNIPROT: W5GU67 describes an uncharacterised protein sequence from Chinese Spring Wheat. EBI accession no. EMBL: GU084176 describes Triticum aestivum LRR receptor-like kinase mRNA sequence. This gene is a LRR receptorlike kinase gene. It is responsive to stress and stripe rust disease development. EBI accession no. describes Triticum aestivum LRR receptor like kinase sequence. This gene is a LRR receptor-like kinase gene. These publications do not disclose recombinant constructs and are not concerned with FHB resistance. Furthermore, none of the sequences disclosed are equivalent to the sequence of SEQUENCE ID NO. 1 of the current invention nor are they functional variants or functional fragments thereof as defined herein.

CN102586291 discloses a sequence encoding LRR receptor kinase from Chinese wheat cv. Wangshuibai. This sequence is not equivalent to the sequence of SEQUENCE ID NO. 1 of the current invention nor is it a functional variant or functional fragment.

WO2015/184331 discloses a sequence encoding an LRR receptor kinase, present within the fhbl QTL located in 3B chromosome. This sequence is not equivalent to the sequence of SEQUENCE ID NO. 1 of the current invention nor is it a functional variant or functional fragment. WO2016008942 discloses a sequence located in wheat chromosome 4A. It is not an LRR receptor like kinase gene nor is it at all related to FHB resistance. This sequence is not equivalent to the sequence of SEQUENCE ID NO. 1 of the current invention nor is it a functional variant or functional fragment.

It is an object of the current invention to provide a gene which provides FHB resistance in plants. No such kinase has been described to date for this disease.

Summary of the Invention

A first aspect of the invention provides a recombinant construct comprising (or consisting of) a nucleotide sequence of SEQUENCE ID NO. 1 or a functional variant or functional fragment thereof. Preferably, the functional variant has at least 30% sequence identity with SEQUENCE ID N0.1 .

Preferably, the functional variant has at least 70% sequence identity with SEQUENCE ID N0.1 .

Preferably, the functional variant has at least 90% sequence identity with SEQUENCE ID N0.1 .

A recombinant host cell comprising a construct of the invention and as described herein is also provided by a further aspect of the invention.

The invention also provides a transformation platform comprising a recombinant construct of the invention. The invention also provides plant material genetically transformed or modified with a nucleotide, recombinant construct or transformation platform of the invention. Typically, the plant material comprises a plant cell carrying a transgene, in which the transgene comprises (or consists of) a nucleotide sequence of SEQUENCE ID NO. 1 or a functional variant or a functional fragment thereof.

The invention also provides a method of genetically transforming a plant material comprising the steps of transforming a cell or cells of the plant material with a nucleotide, recombinant construct or transformation platform of the invention.

Preferably, the transformed cell (or cells) is capable of overexpression of the nucleotide sequence of SEQUENCE ID NO. 1 or a functional variant thereof. The invention also provides a method of producing a transgenic plant or plant material comprising the steps of genetically transforming a plant or plant material according to a method of the invention.

Preferably, the transgenic plant or plant material is resistant to FHB or has enhanced resistance to FHB compared to non-modified or non-transgenic plants.

Typically, the plant material is selected from the group comprising a plant cell, plant cell culture, plant tissue, plant or seed for a plant.

Preferably, the plant is a cereal. Typically, said cereal is selected from the group comprising maize, rice, wheat, barley, sorghum, millet, oats, soybean and rye. Preferably, the cereal is wheat.

A further aspect of the invention provides an isolated nucleotide sequence comprising (or consisting of) SEQUENCE ID NO. 1 or a functional variant thereof or functional fragment thereof. Preferably, the functional variant has at least 55% sequence identity with SEQUENCE ID N0.1 .

Preferably, the functional variant has at least 70% sequence identity with SEQUENCE ID N0.1 .

Preferably, the functional variant has at least 90% sequence identity with SEQUENCE ID N0.1 .

A further aspect of the invention provides an isolated peptide comprising (or consisting of) SEQUENCE ID NO. 2 or a functional variant thereof or a functional fragment thereof.

The invention also provides an isolated protein encoded by the nucleotide of the invention or having a sequence of SEQUENCE ID NO. 2 or a functional variant thereof or a functional fragment thereof.

Preferably, the functional variant has at least 70% sequence identity with SEQUENCE ID NO.2. The isolated nucleotide or peptide is for enhancing or providing FHB resistance in plants or plant material.

Definitions

Where used herein and unless specifically indicated otherwise, the following terms are intended to have the following meanings in addition to any broader (or narrower) meanings the terms might enjoy in the art:

Unless otherwise required by context, the use herein of the singular is to be read to include the plural and vice versa. The term "a" or "an" used in relation to an entity is to be read to refer to one or more of that entity. As such, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.

In the specification, the terms "comprise, comprises, comprised and comprising" or any variation thereof and the terms "include, includes, included and including" or any variation thereof are considered to be totally interchangeable and they should all be afforded the widest possible interpretation and vice versa. "Tal_RRK-6D" when used here in means a gene that is capable of enhancing or providing resistance to FHB in plants. It is a transmembrane kinase protein belonging to the LRR-RLK family. It has a nucleotide sequence of 3096 nucleotides in length and an amino acid sequence of 1031 amino acids in length and has a signal peptide, leucine rich repeats (LLR) domain, a transmembrane domain and a kinase domain. It has a nucleotide sequence of SEQ ID NO. 1 or a variant thereof.

"FHB resistance" as defined herein is the reduction of FHB growth on or in the plant. FHB resistance may be measured by a decrease, or an absence, of FHB symptoms in plants. This may be determined by the method of Example 2.

The phrase "FHB symptoms" when used herein refers to an effect of infection with FHB and includes, but is not limited to, one or more of damage of spikelets, premature discolouration and/or bleaching of spikelets, deoxynivalenol mycotoxin contamination of grain, and shrivelling and/or wrinkling of kernels. Methods of analysing the phenotypic effects are known in the art.

As used herein the term "variant thereof" should be understood to mean a sequence which is substantially identical to a given sequence, but which is altered in respect of one or more amino acid residues or nucleotide residues compared to the given sequence, in such a way so as not to significantly alter the claimed function. Typically, the variant is a (nucleotide or amino acid) sequence having from about 30% to about 99% sequence identity with a given sequence. Generally, the variant is a (nucleotide or amino acid) sequence having from about 70% to about 99% sequence identity, preferably 70, 75, 80, 85, 86, 88, 87, 89,90, 91 , 92, 93, 94, 95, 96, 97, 98 or 99%, sequence identity with a given sequence and which is typically capable of enhancing or providing resistance to FHB in plants, i.e. variant is a functional variant. Such alterations include, insertion, addition, deletion and/or substitution of an amino acid residue(s), or a nucleotide residue(s). There may be 1 , 2, 3, 4, or 5 alterations. It will be appreciated that such variants may be naturally occurring variants or may be a non-natural variant. The term variant also includes a fragment of a sequence. In relation to a variant of a peptide, the insertion, addition and substitution with natural and modified amino acids are envisaged. The variant may have conservative amino acid changes, wherein the amino acid being introduced is similar structurally, chemically, or functionally to that being substituted.

The term "functional variant" when used herein is taken to mean a variant of SEQUENCE ID NO. 1 or SEQUENCE ID NO. 2, which is capable of enhancing or providing resistance to FHB in plants.

The term "fragment" means a segment of a given sequence. Typically, the fragment has from about 10 to 1000 contiguous amino acids, preferably about 50, 100, 200, 300, 400, 500, 600, 700, 800, or 900 amino acids. Typically, the fragment has from 10 to 3000 contiguous nucleotides preferably about 100, 250, 500, 750, 1000, 1250, 1500, 1750, 2000, 2250, 2500 or 2750 nucleotides. The fragment is a functional fragment, i.e., it is a segment of SEQUENCE ID NO. 1 or SEQUENCE ID NO. 2 which is capable of enhancing or providing resistance to FHB in plants. Functional fragments of functional variants of the invention are also provided.

In terms of "sequence homology", the term should be understood to mean that a variant (or homolog) which shares a defined percent similarity or identity with a reference sequence when the percentage of aligned residues of the variant (or homolog) are either identical to, or conservative substitutions of, the corresponding residues in the reference sequence and where the variant (or homolog) shares the same function as the reference sequence.

In this specification, "homology", "identity" or "similarity" refers to the relationship between two peptides or two nucleotide sequences based on an alignment of the sequences. The term "identity" when used herein means the percentage of identical, or conservative substitutions of, amino acid or nucleotide residues at corresponding positions in two sequences when the sequences are aligned and is across the entire length of the sequence, i.e. a variant (or homolog) that shares 70% sequence identity with a reference sequence is one in which any 70% of aligned residues of the variant (or homolog) are identical to, or conservative substitutions of, the corresponding residues in the reference sequence across the entire length of the sequence. For sequence comparison, one sequence acts as a reference sequence, to which test sequences are compared. This alignment and the percent homology, similarity or sequence identity can be determined using software programs known in the art, for example, BLAST, EMBOSS Needle or Clustal Omega, using default parameters. Details of these programs can be found at the following Internet address:http://www. ncbi.nlm.nih.gov. As used herein, the term "genetically modified" as applied to a cell, including a microorganism, means genetically engineered using recombinant DNA technology, and generally involves the step of synthesis of a suitable expression vector (see below) and then transfecting (i.e. stably or transiently) the expression vector into a host cell (generally stable transfection).

As used herein, the term "recombinant cell", "transformed cell", "recombinant plant" or "transformed plant" refers to a cell or plant comprising an exogenous nucleic acid stably integrated into the cellular genome that comprises a nucleotide sequence coding for TaLRRK- 6D. In another embodiment, it may be a cell comprising a non-integrated (i.e., episomal) exogenous nucleic acid, such as a plasmid, cosmid, phagemid, or linear expression element, which comprises a sequence coding suitable for expression of a gene. In other embodiments, the present invention provides a cell line produced by stably transfecting a host cell, such as a plant host cell, with a plasmid comprising an expression vector of the invention. In one embodiment, the cell is engineered for heterologous expression of a gene.

The term "encode" as it is applied to nucleotide sequences refers to a nucleotide which is said to "encode" a polypeptide or peptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for the polypeptide and/or a fragment thereof.

The terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms also apply to amino acid polymers in which one or more amino acid residues is a modified residue, or a non-naturally occurring residue, such as an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. The peptide may or may not be "isolated", that is to say removed from the components which exist around it when naturally occurring.

The term "amino acid" as used herein refers to naturally occurring and synthetic amino acids, as well as amino acid analogues and amino acid mimetics that have a function that is similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those modified after translation in cells (e.g. hydroxyproline, gammacarboxyglutamate, and O-phosphoserine). The phrase "amino acid analogue" refers to compounds that have the same basic chemical structure (an alpha carbon bound to a hydrogen, a carboxy group, an amino group, and an R group) as a naturally occurring amino acid but have a modified R group or modified backbones (e.g. homoserine, norleucine, methionine sulfoxide, methionine methyl sulphonium). The phrase "amino acid mimetic" refers to chemical compounds that have different structures from, but similar functions to, naturally occurring amino acids. It is to be appreciated that, owing to the degeneracy of the genetic code, nucleic acid molecules encoding a particular polypeptide may have a range of polynucleotide sequences. For example, the codons GCA, GCC, GCG and GCT all encode the amino acid alanine. The term "nucleic acid molecule" when used herein to include unmodified DNA or RNA or modified DNA or RNA. For example, the nucleic acid molecules or polynucleotides of the disclosure can be composed of single- and double stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically double-stranded or a mixture of single- and double-stranded regions. In addition, the nucleic acid molecules can be composed of triplestranded regions comprising RNA or DNA or both RNA and DNA. The nucleic acid molecules of the disclosure may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritiated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus "nucleic acid molecule" embraces chemically, enzymatically, or metabolically modified forms. The term "polynucleotide" shall have a corresponding meaning.

In this specification, the term "plant material" should be understood to mean any constituent of a plant comprising plant cells, including a plant cell, plant cell culture, plant tissue, plant, or seed from a plant.

The term "cell" should be understood to mean a cell from a plant. In a particularly preferred embodiment, the cell is a plant cell selected from the group consisting of: maize, rice, wheat, barley, sorghum, millet, oats, soybean and rye. The term "transgenic cell" should be understood to mean a cell that comprises a transgene incorporated, ideally stably incorporated, into its genome.

The term "transformation platform" should be understood to mean the genetic machinery required to transfer the transgene into a cell, and generally comprises an organism, for example a bacteria, capable of mediating cellular transformation and containing a recombinant construct of the invention. Examples of transformation platforms include E.coli, A. tumefaciens, E. adhaerens, and certain "transbacter" strains of bacteria. Other examples include: biolistic transformation and floral dipping.

The term "transgene" should be understood to mean the nucleotide of the invention, and functional variants thereof. The term "overexpression" refers to expression of a gene or protein in an increased quantity relative to the wild-type. In one embodiment, the expression may be enhanced by transfection of an expression vector containing the necessary machinery to express Tal_RRK-6D into a host cell. The expression may be enhanced by a promoter to produce multiple copies of mRNA and large quantities of the selected product Tal_RRK-6D. The host cell may already express endogenous Tal_RRK-6D.

The phrase "nucleotide of the invention" when used herein refers to SEQUENCE ID NO. 1 or a functional variant thereof or a functional fragment thereof.

The phrases "amino acid sequence of the invention" or "peptide of the invention" when used herein refer to SEQUENCE ID NO. 2 or a functional variant thereof or a functional fragment thereof.

Brief Description of the Drawings

The invention will be more clearly understood from the following description of an embodiment thereof, given by way of example only, with reference to the accompanying drawings, in which: Figure 1 A illustrates a genetic map of the Poeceace Family.

Figure 1 B is a homologue chart across 5 the cereal family.

Figure 2A illustrates the transmembrane kinase protein, Tal_RRK-6D.

Figure 2B is a LRR-RLK family chart.

Figure 3 is a graph of post inoculation expression levels for TaLRRK-6D in wheat heads inoculated with Fusarium and treated with mycotoxin DON.

Figure 4 illustrates the alignment of cloned 1300bp specific to Tal_RRK-6D.

Figure 5 illustrates the position of the fragments within the mRNA encoding the wheat TaLRRK-6D on wheat chromosomes 6DL targeted for gene silencing and qRT-PCR for virus induced gene silencing (VIGS) studies. Numbers indicate bp positions in the TaLRRK-6D mRNA sequence.

Figure 6 is a pictorial representation of the two VIGS constructs and specificity to TaLRRK- 6D. The two VIGS constructs (BSMV:LRR1 and BSMV:LRR2) were aligned with TaLRRK-6D using clustalW2 multiple alignment in Clonemanager v.9.0 to validate that BSMV:LRR1 and BSMV:LRR2 were specific to silence TaLRRK-6D. Figure 7 is a chart illustrating TaLRRK-6D expression in the non-toxin treated plants (mock), whether in the control (BSMV:00) or silenced plants (BSMV:LRR1 and BSMV:LRR2). Figure 8 illustrates FHB symptoms in Remus (susceptible) and CM (resistant) wheat heads 0, 7, 14 and 21 days post inoculation (FHB-treated, BSMV:00-treated plants).

Figure 9 illustrates FHB induced damage of spikelets in plants treated with BSMV:LRR1 and BSMV:LRR2 and the non-silenced plants BSMV:00. Figure 10 illustrates FHB-induced damage in TaLRRK-6D silenced and BSMV:00 treated spikelets.

Figure 1 1 illustrates lesions in barley cv.Akashinriki silenced lines with constructs BSMV:LRR1 and BSMV:LRR2 and in BSMV:00 treated lines.

Figure 12 is a graph illustrating the number of conidia developed on the leaves of BSMV:LRR1 and BSMV:LRR2 silenced lines and on the wild type cv. Akashinriki treated with BSMV:00.

Detail Description of the Invention

The current inventors have surprisingly found that Tal_RRK-6D is highly induced in response to FHB in wheat heads of resistant cultivars and that gene silencing leads to an increase in FHB symptoms. The current invention provides a gene for resistance to Fusarium head blight (FHB) in plants.

More specifically, the current invention provides a specific wheat (genome D homologue) of a leucine rich receptor kinase gene, Tal_RRK-6D and a variant thereof for resistance to FHB in plants. The gene of the invention is termed Tal_RRK-6D. Tal_RRK-6D is restricted to the Poaceace Family (Figure 1 ). It is found across the plant species but is confined to cereal family (Figure 2).

Advantageously, as Tal_RRK-6D is a native gene from the cultivars, the risk of resistance breakdown is greatly reduced. This provides longer and sustainable resistance in all conditions and genetic background.

Tal_RRK-6D is a transmembrane kinase protein belonging to the LRR-RLK family. It has an amino acid sequence of 1031 amino acids in length and has a signal peptide, leucine rich repeats (LLR) domain, a transmembrane domain and a kinase domain.

The gene of the invention, Tal_RRK-6D, has a nucleotide sequence of SEQUENCE ID N0.1 as follows:

ATGTCTGACCAATCCGTGAAACTCAACATGCT TCT TCTGCTGGCGT T TCTGCTGCTGTCT TA TGGAGCTGGCAATGCCCGT TGCTCAACTGT TCATGCGAACATCACAGACAT TCTCTCCT TGC TCCGAT TCAAAAGGTCCACCCACGATCCAACAGGT TCCT TGAGGAACTGGAACCGAAGCATC CATTACTGCAAGTGGAATGGTGTCTCCTGCAGCTTACTGAATCCAGGGCGGGTGGCGGCT TT GGATCTCCCTGGCCAAAACTTGTCAGGTCAAGTCAACCCTTCTCTTGGGAACATAACGTT CC TTAAGCGCCTGAATTTGTCCTCCAATGGCTTCTCCGGCCAGTTACCTGACGCTTCTCAGC AT GAGCTCCTACTTATTCCAAGGGATAATCCCCGATTCACTCACACAATTTTCGAACCTACA GC TCCTGAATTTGTCCTACAATGGCTTCTCCGGCCAGTTACCTCCTCTGAACCAGCTTCCCG AG CTGGTGGTTCTCAGCTTGAAATCCAATTTATTCCAAGGGATAATCCCCGACTCACTCACA AA CTGTTCGAACCTCACGTTTGTGGATCTTTCAAGAAACATGCTAGAAGGCTCAATCCCGGC GA AAATAGGTTCGCTTTACAATCTAATGAATTTAGACCTTTCAATGAAATGACTCACCGGGG TC ATACCACCAACCATCAGCAATGCCACCAAGCTACAATTTCTCATTCTTCAAGAAAACAAA CT AGAGGGAAGCATACCCATGAACTAGACTTGGACAATTGTCCAACATTATCGGCTTTACTG TT GGTAGCAATAGGCTCTCAGGTCAAATACCAGCATCAATCTTTAATCTTACTTTGCTCCGA GT GCCTGGCTTGTACGCAAATAGACTACAAATGGCGGCACTGCCACTTGACATTGGCCACAC CC TCCCTAATCTCCAAAATATTACTTTGGGCCAAAACATGCTTGAAGGTCCTATCCCAGCGT CG CCAAGTAACATTTCAAGCCTGCAATAATCTCAGTTATCTAATAACAGTTTCACTGGAGAA AT TCCTAGTTTCGGAAAGCTACAGAAACTTGTATACCCTCACCTTGCGGACAATAAGCTGGA GT CAAGTGACAGCCAAAGATGGGAATCTTTATATGGACTGGCAAACTGCAGTCATCCTTAAT CG CTCAGATTCAAGAATAATCAGCCGCAAGGAGTCATACCAAATTCGGGGAGTCATACCAAA TT CGGTAGGTAAATTGTCCCCTAAACTTGAACTTCTACATCTGGGTGGAAACAATCTATCAG GA ATAGTTCCTTCAAGCATAGGAAACCTTGATGGCTTAATAGATTTGGATCTTAGCACAAAC AG TTTCAATGGTACAATTGAAGGATGGGTAGGAAGTCTTAAAAAACTACAATCTCTAGATCT TC ATGGAAACAATTTCGTTGGAGCCATTCCACCCTCTTTTGGCAACCTTACTGAGCTAACAT AT CTGTATTTAGCAAAAAATGAATTTGAAGGGACCATACCTCCCATTCTCGGGAAACTTAAA AG ACTCTCAGCCATGGACCTTAGCTATAATAATCTTCAAGGTGACATTCCTCCAGAACTCAG TG GGCTTACACAACTCCGTACACTGAATCTTTCATCTAACAGACTTACAGGAGAAATTCCTG TT GATCTGAGCCAGTGTCAAGACCTGGTAACCATCCAAATGGACCATAATAACTTGACGGGT GA CATTCCAACCACTTTTGGTGACCTTATGAGCTTGAACATGCTCAGCCTTTCCTATAATGA TT TATCAGGGGCCATCCCTGTAAGTCTTCAACATGTCAGCAAGTTGGACTTATCTCATAATC AC CTCCAAGGAGAAATCCCACCAGAAGGAGTGTTTAGGAATGCCTCAGCCGTTTCGCTTGCT GG CAATTCAGAGCTTTGTGGAGGGGTGTCGGAACTGCATATGCCTCCATGCCCAGTTGCTTC TC AGAGAACTAAGATACGATATTACTTGATCAGGGTATTGATACCATTATTTGGCTTCATGT CG CTCCTATTATTGGTCTACTTTCTAGTCCTCGAGAGGAAAATGAGAAGAACAAGATATGAA TC ACAGGCTCCTTTGGGTGAGCATTTCCCTAAAGTTTCTTACAATGATCTGGTTGAAGCAAC AA AGAACTTTTCCGAGTCTAACCTGCTTGGGAAAGGAAGCTATGGTACAGTGTACAAGGGAA AC TTGGTGCAGCATAAGTTGGAAGTGGCAGTGAAGGTTTTTAACCTTGAGATGCAAGGCGCG GA GAGAAGCTTCATGCCAGAATGTGAAGCGCTGAGAAGCGTTCAACACCGGAATCTTGTTTC CA TCATAACTGCATGTTCTACTGTTGATAGCGACGGTAGAGCTTTCAGGGCCCTAATTTACG AG TTCATGCCCAAGGGGAACTTGGACACGTGCCTTCATCACAAGGGGGACGGCAAAGCTGAT AA GCATCTGACTTTAACTCAAAGAATCGGCATAGCTGTCAACATAGCAGATGCACTGGACTA TT TACATAATGACAGCGAAAACCCCATCATCCATTGTGATCTGAAGCCCAGCAATATTCTTC TT GATGAGGACATGGTTGCTCATTTGGGGGATTTCGGTATTGCAAGGATTTTTCTTGATTCT GG GCTAAGACCAGCAAGCTCGACGAGTTCAATTGGTGTAAAAGGAACGATAGGCTATATCCC AC CAGAGTACGGCGGGGGAGGCCGTATATCTACTTCTGGGGATGTCTACAGTTTTGGGATAG TG CTGCTGGAGATGTTGACTGGCAAAAGGCCAACAGATCCTATGTTTATGGATGGACTGGAC AT CGTCAACTTCGTGGGCAACAAGTTTCCACATCAAATACATGAAGTGATTGACATTTATCT AA AAGGAGAGTGCGAGTCAGAAGATTCGGTTCATCAGTGCCTCGTGTCTCTGCTGCAAGTAG CA GTCTCCTGCACACACTCCATCCCCGGCGAAAGAGCGAACATTAGAGATACAGCTAGCAAG CT CCAGGAAATTAAGGCGTCATATCTTGGAAGGAAGGCAAAGATAAATCCTTCAGTTTAA

Tal_RRK-6D has an amino acid sequence of SEQUENCE ID NO.2 as follows:

MSDQSVKLNMLLLLAFLLLSYGAGNARCSTVHANITDILSLLRFKRSTHDPTGSLRN WNRSI HYCKWNGVSCSLLNPGRVAALDLPGQNLSGQVNPSLGNITFLKRLNLSSNGFSGQLPDAS QH ELLLIPRDNPRFTHTIFEPTAPEFVLQWLLRPVTSSEPASRAGGSQLEIQFIPRDNPRLT HK LFEPHVCGSFKKHARRLNPGENRFALQSNEFRPFNEMTHRGHTTNHQQCHQATI SHSSRKQT RGKHTHELDLDNCPTLSALLLVAIGSQVKYQHQSLILLCSECLACTQIDYKWRHCHLTLA TP SLI SKILLWAKTCLKVLSQRRQVTFQACNNLSYLITVSLEKFLVSESYRNLYTLTLRTI SWS QVTAKDGNLYMDWQTAVILNRSDSRI I SRKESYQIRGVIPNSVGKLSPKLELLHLGGNNLSG IVPSSIGNLDGLIDLDLSTNSFNGTIEGWVGSLKKLQSLDLHGNNFVGAIPPSFGNLTEL TY LYLAKNEFEGTIPPILGKLKRLSAMDLSYNNLQGDIPPELSGLTQLRTLNLSSNRLTGEI PV DLSQCQDLVTIQMDHNNLTGDIPTTFGDLMSLNMLSLSYNDLSGAIPVSLQHVSKLDLSH NH LQGEIPPEGVFRNASAVSLAGNSELCGGVSELHMPPCPVASQRTKIRYYLIRVLIPLFGF MS LLLLVYFLVLERKMRRTRYESQAPLGEHFPKVSYNDLVEATKNFSESNLLGKGSYGTVYK GN LVQHKLEVAVKVFNLEMQGAERSFMPECEALRSVQHRNLVS I ITACSTVDSDGRAFRALIYE FMPKGNLDTCLHHKGDGKADKHLTLTQRIGIAV IADALDYLHNDSENPI IHCDLKPS ILL DEDMVAHLGDFGIARIFLDSGLRPASSTSS IGVKGTIGYIPPEYGGGGRI STSGDVYSFGIV LLEMLTGKRPTDPMFMDGLDIVNFVGNKFPHQIHEVIDIYLKGECESEDSVHQCLVSLLQ VA VSCTHS IPGERA IRDTASKLQEIKASYLGRKAKINPSV

In an embodiment of the invention, a variant of the gene is also provided. Typically, said variant has at least about 30% sequence identity with SEQUENCE ID NO. 1 . In an embodiment, the variant has at least about 40%, 50%, 60% or 70 % sequence identity to SEQUENCE ID NO. 1. In a preferred embodiment, the variant comprises at least about 70, 75, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity with SEQUENCE ID NO. 1, typically between from about 91.5 % to about 95% sequence identity with SEQUENCE ID NO.1. Typically, the variant is a functional variant.

The variant may have a sequence comprising (or consisting of) SEQUENCE ID NO.3, 10 SEQUENCE ID NO.4, SEQUENCE ID NO.5, SEQUENCE ID NO.6, SEQUENCE ID NO.7, SEQUENCE ID NO.8, SEQUENCE ID NO.9 or SEQUENCE ID NO.10.

Preferably, the variant comprises (or consists of) a sequence of SEQUENCE ID NO.3, SEQUENCE ID NO.4 or SEQUENCE ID NO.5.

SEQUENCE ID NO.3 is as follows:

ATGTCTGACCAATCCGTGAAACTCAACATGCTTCTTCTGCTGGCGTTTCTGCTGCTG TCTTA TGGAGCTGGCAATGCCCGTTGCTCAACTGTTCATGCGAACATCACAGACATTCTCTCCTT GC TCCGATTCAAAAGGTCCACCCACGATCCAACAGGTTCCTTGAGGAACTGGAACCGAAGCA TC CATTACTGCAAGTGGAATGGTGTCTCCTGCAGCTTACTGAATCCAGGGCGGGTGGCGGCT TT GGATCTCCCTGGCCAAAACTTGTCAGGTCAAGTCAACCCTTCTCTTGGGAACATAACGTT CC TTAAGCGCCTGAATTTGTCCTCCAATGGCTTCTCCGGCCAGTTACCTCCTCTGAGTCAGC TC CATGAGCTGACGCTTCTTGACATGAGCTCTAACTTATTCCAAGGGATAATCCCCGATTCA CT CACACAATTTTCGAACCTACAGCTCCTGAATTTGTCCTACAATGGCTTCTCCGGCCAGTT AC CTCCTCTGAACCAGCTTCCCGAGCTGGTGGTTCTTGACTTGAAATCCAATTTATTCCAAG GG ATAATCCCCGACTCACTCACAAACTGTTCGAACCTCACGTTTGTGGATCTTTCAAGAAAC AT GCTAGAAGGCTCAATCCCGGCGAAAATAGGTTCGCTTTACAATCTAATGAATTTAGACCT TT CTAGGAATAAACTCACCGGGGTCATACCACCAACCATCAGCAATGCCACCAAGCTACAAT TT CTCATTCTTCAAGAAAATGAACTAGAGGGAAGCATACCCAGTGAGCTTGGACAATTGTCC AA CATGATCGGCTTTACTGTTGGTAGCAATAGGCTCTCAGGTCAAATACCAGCATCAATCTT TA ATCTTACTTTGCTCCGAGTGCTAGGCTTGTACGCAAATAGACTACAAATGGCGGCACTGC CA CTTGACATTGGCCACACCCTCCCTAATCTCCAAAATATTACTTTGGGCCAAAACATGCTT GA AGGTCCTATCCCAGCGTCGCTAGGTAACATTTCAAGCCTGCAATTAATAGAGTTATCTAA TA ACAGTTTCACTGGAGAAATTCCTAGTTTCGGAAAGCTACAGAAACTTGTATACCTAAACC TT GCGGACAATAAGCTGGAGTCAAGTGACAGCCAAAGATGGGAATCTTTATATGGACTAACA AA CTGCAGTCATCTAAAATCGCTCAGATTCAAGAATAATCAGCTGAAAGGAGTCATACCAAA TT CGGTAGGTAAATTGTCCCCTAAACTTGAACTTCTACATCTGGGTGGAAACAATCTATCAG GA ATAGTTCCTTCAAGCATAGGAAACCTTGATGGCTTAATAGATTTGGATCTTAGCACAAAC AG TTTCAATGGTACAATTGAAGGATGGGTAGGAAGTCTTAAAAAACTACAATCTCTAGATCT TC ATGGAAACAATTTCGTTGGAGCCATTCCACCCTCTTTTGGCAACCTTACTGAGCTAACAT AT CTGTATTTAGCAAAAAATGAATTTGAAGGGACCATACCTCCCATTCTCGGGAAACTTAAA AG ACTCTCAGCCATGGACCTTAGCTATAATAATCTTCAAGGTGACATTCCTCCAGAACTCAG TG GGCTTACACAACTCCGTACACTGAATCTTTCATCTAACAGACTTACAGGAGAAATTCCTG TT GATCTGAGCCAGTGTCAAGACCTGGTAACCATCCAAATGGACCATAATAACTTGACGGGT GA CATTCCAACCACTTTTGGTGACCTTATGAGCTTGAACATGCTCAGCCTTTCCTATAATGA TT TATCAGGGGCCATCCCTGTAAGTCTTCAACATGTCAGCAAGTTGGACTTATCTCATAATC AC CTCCAAGGAGAAATCCCACCAGAAGGAGTGTTTAGGAATGCCTCAGCCGTTTCGCTTGCT GG CAATTCAGAGCTTTGTGGAGGGGTGTCGGAACTGCATATGCCTCCATGCCCAGTTGCTTC TC AGAGAACTAAGATACGATATTACTTGATCAGGGTATTGATACCATTATTTGGCTTCATGT CG CTCCTATTATTGGTCTACTTTCTAGTCCTCGAGAGGAAAATGAGAAGAACAAGATATGAA TC

ACAGGCTCCTTTGGGTGAGCATTTCCCTAAAGTTTCTTACAATGATCTGGTTGAAGC AACAA AGAACTTTTCCGAGTCTAACCTGCTTGGGAAAGGAAGCTATGGTACAGTGTACAAGGGAA AC TTGGTGCAGCATAAGTTGGAAGTGGCAGTGAAGGTTTTTAACCTTGAGATGCAAGGCGCG GA GAGAAGCTTCATGCCAGAATGTGAAGCGCTGAGAAGCGTTCAACACCGGAATCTTGTTTC CA TCATAACTGCATGTTCTACTGTTGATAGCGACGGTAGAGCTTTCAGGGCCCTAATTTACG AG TTCATGCCCAAGGGGAACTTGGACACGTGCCTTCATCACAAGGGGGACGGCAAAGCTGAT AA GCATCTGACTTTAACTCAAAGAATCGGCATAGCTGTCAACATAGCAGATGCACTGGACTA TT TACATAATGACAGCGAAAACCCCATCATCCATTGTGATCTGAAGCCCAGCAATATTCTTC TT GATGAGGACATGGTTGCTCATTTGGGGGATTTCGGTATTGCAAGGATTTTTCTTGATTCT GG GCTAAGACCAGCAAGCTCGACGAGTTCAATTGGTGTAAAAGGAACGATAGGCTATATCCC AC CAGAGTACGGCGGGGGAGGCCGTATATCTACTTCTGGGGATGTCTACAGTTTTGGGATAG TG CTGCTGGAGATGTTGACTGGCAAAAGGCCAACAGATCCTATGTTTATGGATGGACTGGAC AT CGTCAACTTCGTGGGCAACAAGTTTCCACATCAAATACATGAAGTGATTGACATTTATCT AA AAGGAGAGTGCGAGTCAGAAGATTCGGTTCATCAGTGCCTCGTGTCTCTGCTGCAAGTAG CA GTCTCCTGCACACACTCCATCCCCGGCGAAAGAGCGAACATTAGAGATACAGCTAGCAAG CT CCAGGAAATTAAGGCGTCATATCTTGGAAGGAAGGCAAAGATAAATCCTTCAGTT

SEQUENCE ID NO.4 is as follows:

(Cultivar Remus chromosome 6D variant - Tal_RRK-6D)

ATGTCTGACCAATCCGTGAAACTCAACATGCTTCTTCTGCTGGCGTTTCTGCTGCTG TCTTA TGGAGCTGGCAATGCCCGTTGCTCAACTGTTCATGCGAACATCACAGACATTCTCTCCTT GC TCCGATTCAAAAGGTCCACCCACGATCCAACAGGTTCCTTGAGGAACTGGAACCGAAGCA TC CATTACTGCAAGTGGAATGGTGTCTCCTGCAGCTTACTGAATCCAGGGCGGGTGGCGGCT TT GGATCTCCCTGGCCAAAACTTGTCAGGTCAAGTCAACCCTTCTCTTGGGAACATAACGTT CC TTAAGCGCCTGAATTTGTCCTCCAATGGCTTCTCCGGCCAGTTACCTGACGCTTCTCAAC AT GAGCTCTTACTTATTCCAAGGGATAATCCCCGATTCACTCACACAATTTTCGAACCTACA GC TCCTGAATTTGTCCTACAATGGCTTCTCCGGCCAGTTACCTCCTCTGAACCAGCTTCCCG AG CTGGTGGTTCTCAACTTGAAATCCAATTTATTCCAAGGGATAATCCCCGACTCACTCACA AA CTGTTCGAACCTCACGTTTGTGGATCTTTCAAGAAACATGCTAGAAGGCTCAATCCCGGC GA AAATAGGTTCGCTTTACAATCTAATGAATTTAGACCTTTCAACGAAATGACTCACCGGGG TC ATACCACCAACCATCAGCCAATGCCACCAAGCTACAATTTCTCATTCTTCAAGAAAATGC AC CTAGAGGGGAAGCATACCCAGCTAGCTTGGACAATTGTCCAACATGATTCGGCTTTACTG GT TGGAAGCAATAAGGCTCTCAGGTCAAATGCCCAGCATGCAATCTTTAAATCTTACTTTGG AT CCAAGTGCTTAGGTTGGTACGCCAACAAAACTACCAAATGGCGGGCACTGCCAATTAGAA TT

GGGCCAAACCCTCCCCTAATTTCCAAAAAATTAACTTTGGGCCCAAAAAAGGCTATG AAGGT CCTATCCCAGCGTCGCTCGGTAACATTTCAAGCCTGCAATCTCCAAAGTTATCCAATTAC AG TTTCACTGGAGAAATTCCTAGTTTCGGAAAGCTACAGAAACTTGTATACCTATACCTTGC GG ACAATAAGCTGGAGTCAAGTGACAGCCAAAGATGGGAATCTTTATATGGACCAGCAAACT GC AGTCATCCACAATCGCTCAGATTCAAGAATAATCAGCCAGAAGGAGTCTTACCAAATTCG GA GCGTAAATTGTCCCCTAAACTTGAACTTCTACATCTGGGGTGGAAACAATCTATCAGGAA TA GTTCCTTCAAGCTCCGGAAACCTTGATGGCTTAATAGATTTGGATCTTAGCACAAACAGT TT CAATGGTACAATTGAAGGATGGGTAGGAAGTCTTAAAAAACTACAATCTCTAGATCTTCA TG GAAACAATTTCGTTGGAGCCATTCCACCCTCTTTTGGCAACCTTACTGAGCTAACATATC TG TATTTAGCAAAAAATGAATTTGAAGGGACCATACCTCCCATTCTCGGGAAACTTAAAAGA CT CTCAGCCATGGACCTTAGCTATAATAATCTTCAAGGTGACATTCCTCCAGAACTCAGTGG GC TTACACAACTCCGTACACTGAATCTTTCATCTAACAGACTTACAGGAGAAATTCCTGTTG AT CTGAGCCAGTGTCAAGACCTGGTAACCATCCAAATGGACCATAATAACTTGACGGGTGAC AT TCCAACCACTTTTGGTGACCTTATGAGCTTGAACATGCTCAGCCTTTCCTATAATGATTT AT CAGGGGCCATCCCTGTAAGTCTTCAACATGTCAGCAAGTTGGACTTATCTCATAATCACC TC CAAGGAGAAATCCCACCAGAAGGAGTGTTTAGGAATGCCTCAGCCGTTTCGCTTGCTGGC AA TTCAGAGCTTTGTGGAGGGGTGTCGGAACTGCATATGCCTCCATGCCCAGTTGCTTCTCA GA GAACTAAGATACGATATTACTTGATCAGGGTATTGATACCATTATTTGGCTTCATGTCGC TC CTATTATTGGTCTACTTTCTAGTCCTCGAGAGGAAAATGAGAAGAACAAGATATGAATCA CA GGCTCCTTTGGGTGAGCATTTCCCTAAAGTTTCTTACAATGATCTGGTTGAAGCAACAAA GA ACTTTTCCGAGTCTAACCTGCTTGGGAAAGGAAGCTATGGTACAGTGTACAAGGGAAACT TG GTGCAGCATAAGTTGGAAGTGGCAGTGAAGGTTTTTAACCTTGAGATGCAAGGCGCGGAG AG AAGCTTCATGCCAGAATGTGAAGCGCTGAGAAGCGTTCAACACCGGAATCTTGTTTCCAT CA TAACTGCATGTTCTACTGTTGATAGCGACGGTAGAGCTTTCAGGGCCCTAATTTACGAGT TC ATGCCCAAGGGGAACTTGGACACGTGCCTTCATCACAAGGGGGACGGCAAAGCTGATAAG CA TCTGACTTTAACTCAAAGAATCGGCATAGCTGTCAACATAGCAGATGCACTGGACTATTT AC ATAATGACAGCGAAAACCCCATCATCCATTGTGATCTGAAGCCCAGCAATATTCTTCTTG AT GAGGACATGGTTGCTCATTTGGGGGATTTCGGTATTGCAAGGATTTTTCTTGATTCTGGG CT AAGACCAGCAAGCTCGACGAGTTCAATTGGTGTAAAAGGAACGATAGGCTATATCCCACC AG AGTACGGCGGGGGAGGCCGTATATCTACTTCTGGGGATGTCTACAGTTTTGGGATAGTGC TG CTGGAGATGTTGACTGGCAAAAGGCCAACAGATCCTATGTTTATGGATGGACTGGACATC GT CAACTTCGTGGGCAACAAGTTTCCACATCAAATACATGAAGTGATTGACATTTATCTAAA AG GAGAGTGCGAGTCAGAAGATTCGGTTCATCAGTGCCTCGTGTCTCTGCTGCAAGTAGCAG TC TCCTGCACACACTCCATCCCCGGCGAAAGAGCGAACATTAGAGATACAGCTAGCAAGCTC CA GAAAAAGGTCGTCAACTGCCCCCTAA

SEQUENCE ID NO.5 is as follows:

2 Cultivar Chinese Spring (CS) chromosome 6D variant - TRIAE_CS42_6DL_TGACv1_527217_AA1700660.1

ATGTCTGACCAATCCGTGAAACTCAACATGCTTCTTCTGCTGGCGTTTCTGCTGCTG TCTTA TGGAGCTGGCAATGCCCGTTGCTCAACTGTTCATGCGAACATCACAGACATTCTCTCCTT GC TCCGATTCAAAAGGTCCACCCACGATCCAACAGGTTCCTTGAGGAACTGGAACCGAAGCA TC CATTACTGCAAGTGGAATGGTGTCTCCTGCAGCTTACTGAATCCAGGGCGGGTGGCGGCT TT GGATCTCCCTGGCCAAAACTTGTCAGGTCAAGTCAACCCTTCTCTTGGGAACATAACGTT CC TTAAGCGCCTGAATTTGTCCTCCAATGGCTTCTCCGGCCAGTTACCTCCTCTGAGTCAGC TC CATGAGCTGACGCTTCTTGACATGAGCTCTAACTTATTCCAAGGGATAATCCCCGATTCA CT CACACAATTTTCGAACCTACAGCTCCTGAATTTGTCCTACAATGGCTTCTCCGGCCAGTT AC CTCCTCTGAACCAGCTTCCCGAGCTGGTGGTTCTTGACTTGAAATCCAATTTATTCCAAG GG ATAATCCCCGACTCACTCACAAACTGTTCGAACCTCACGTTTGTGGATCTTTCAAGAAAC AT GCTAGAAGGCTCAATCCCGGCGAAAATAGGTTCGCTTTACAATCTAATGAATTTAGACCT TT CTAGGAATAAACTCACCGGGGTCATACCACCAACCATCAGCAATGCCACCAAGCTACAAT TT CTCATTCTTCAAGAAAATGAACTAGAGGGAAGCATACCCAGTGAGCTTGGACAATTGTCC AA CATGATCGGCTTTACTGTTGGTAGCAATAGGCTCTCAGGTCAAATACCAGCATCAATCTT TA ATCTTACTTTGCTCCGAGTGCTAGGCTTGTACGCAAATAGACTACAAATGGCGGCACTGC CA CTTGACATTGGCCACACCCTCCCTAATCTCCAAAATATTACTTTGGGCCAAAACATGCTT GA AGGTCCTATCCCAGCGTCGCTAGGTAACATTTCAAGCCTGCAATTAATAGAGTTATCTAA TA ACAGTTTCACTGGAGAAATTCCTAGTTTCGGAAAGCTACAGAAACTTGTATACCTAAACC TT GCGGACAATAAGCTGGAGTCAAGTGACAGCCAAAGATGGGAATCTTTATATGGACTAACA AA CTGCAGTCATCTAAAATCGCTCAGATTCAAGAATAATCAGCTGAAAGGAGTCATACCAAA TT CGGTAGGTAAATTGTCCCCTAAACTTGAACTTCTACATCTGGGTGGAAACAATCTATCAG GA ATAGTTCCTTCAAGCATAGGAAACCTTGATGGCTTAATAGATTTGGATCTTAGCACAAAC AG TTTCAATGGTACAATTGAAGGATGGGTAGGAAGTCTTAAAAAACTACAATCTCTAGATCT TC ATGGAAACAATTTCGTTGGAGCCATTCCACCCTCTTTTGGCAACCTTACTGAGCTAACAT AT CTGTATTTAGCAAAAAATGAATTTGAAGGGACCATACCTCCCATTCTCGGGAAACTTAAA AG ACTCTCAGCCATGGACCTTAGCTATAATAATCTTCAAGGTGACATTCCTCCAGAACTCAG TG GGCTTACACAACTCCGTACACTGAATCTTTCATCTAACAGACTTACAGGAGAAATTCCTG TT

GATCTGAGCCAGTGTCAAGACCTGGTAACCATCCAAATGGACCATAATAACTTGACG GGTGA CATTCCAACCACTTTTGGTGACCTTATGAGCTTGAACATGCTCAGCCTTTCCTATAATGA TT TATCAGGGGCCATCCCTGTAAGTCTTCAACATGTCAGCAAGTTGGACTTATCTCATAATC AC CTCCAAGGAGAAATCCCACCAGAAGGAGTGTTTAGGAATGCCTCAGCCGTTTCGCTTGCT GG CAATTCAGAGCTTTGTGGAGGGGTGTCGGAACTGCATATGCCTCCATGCCCAGTTGCTTC TC AGAGAACTAAGATACGATATTACTTGATCAGGGTATTGATACCATTATTTGGCTTCATGT CG CTCCTATTATTGGTCTACTTTCTAGTCCTCGAGAGGAAAATGAGAAGAACAAGATATGAA TC ACAGGCTCCTTTGGGTGAGCATTTCCCTAAAGTTTCTTACAATGATCTGGTTGAAGCAAC AA AGAACTTTTCCGAGTCTAACCTGCTTGGGAAAGGAAGCTATGGTACAGTGTACAAGGGAA AC TTGGTGCAGCATAAGTTGGAAGTGGCAGTGAAGGTTTTTAACCTTGAGATGCAAGGCGCG GA GAGAAGCTTCATGCCAGAATGTGAAGCGCTGAGAAGCGTTCAACACCGGAATCTTGTTTC CA TCATAACTGCATGTTCTACTGTTGATAGCGACGGTAGAGCTTTCAGGGCCCTAATTTACG AG TTCATGCCCAAGGGGAACTTGGACACGTGCCTTCATCACAAGGGGGACGGCAAAGCTGAT AA GCATCTGACTTTAACTCAAAGAATCGGCATAGCTGTCAACATAGCAGATGCACTGGACTA TT TACATAATGACAGCGAAAACCCCATCATCCATTGTGATCTGAAGCCCAGCAATATTCTTC TT GATGAGGACATGGTTGCTCATTTGGGGGATTTCGGTATTGCAAGGATTTTTCTTGATTCT GG GCTAAGACCAGCAAGCTCGACGAGTTCAATTGGTGTAAAAGGAACGATAGGCTATATCCC AC CAGAGTACGGCGGGGGAGGCCGTATATCTACTTCTGGGGATGTCTACAGTTTTGGGATAG TG CTGCTGGAGATGTTGACTGGCAAAAGGCCAACAGATCCTATGTTTATGGATGGACTGGAC AT CGTCAACTTCGTGGGCAACAAGTTTCCACATCAAATACATGAAGTGATTGACATTTATCT AA AAGGAGAGTGCGAGTCAGAAGATTCGGTTCATCAGTGCCTCGTGTCTCTGCTGCAAGTAG CA GTCTCCTGCACACACTCCATCCCCGGCGAAAGAGCGAACATTAGAGATACAGCTAGCAAG CT CCAGGAAATTAAGGCGTCATATCTTGGAAGGAAGGCAAAGATAAATCCTTCAGTTTAA SEQUENCE ID NO.6 is as follows: TRIAE_CS42_2AL_TGACv1_093509_AA0281510.6

ATGAAGCTCTTCGTGCTCGTAGCATGGGCACTGTTGTTATTGTCTCATGGATCTGGA AGCGT CATTTGCGCCGTCCTCCATGGGAACGATACAGATATGCTGTCGCTTCTTGATTTCAAGCG CG CAATCACCGAAGATCCGAAAGGGCTCTTGAGCACATGGAACACCAGCATTCATTTCTGCA AC TGGCAGGGTGTGAAGTGCAGCCTCACAGAGCATGAGCGTGTTGCAGAGCTGGACCTGTCT GA GCAGAGTTTTGTCGGGGAAATCTCTCCTTCCCTTGGAAACATGTCATATCTTACTTATCT TA ACCTTTCCAGAAGCAAGTTCTCTGGTCAGATACCACATTTTGGCCGGCTGCGAGAGCTGG AG TTTCTTGACCTGAGTCACAACTCGCTACAAGGGATTATTCCAGTGACGCTCACAAACTGC TC CAACTTGAGGGCGTTAGACCTCTCAAGAAACTTATTGGTGGGTGAAATTCCCGCAGAAAT AT CCCTTCTCTCCAACCTGACACGCTTGTGGCTTTCTTATAATGATCTTACCGGGGTCATTC CA CCAGGCCTTGGCAATATCACTTCTCTAGAACATGTTATTCTGATGTATAACCGGTTAGAG GG AGGCATTCCTGATGAGTTTGGGAAGTTGTCCAAGATGTCAAACTTACTCCTTGGTGAAAA CA AGCTATCAGGTAGAGTCCCAAAGGCCATTTTTAATCTGTCTCTGCTAAATCAAATGGCGC TG GAGTTGAATATGCTAGTTGGTACTCTACCATCTAACATGGGTGATGCTCTCCCTAACCTC CG ACTTCTTACATTGGGTGGTAACATGCTGGAAGGTCTTATCCCTGACTCATTAGGCAATGC AT CCGAGCTACAGCTGATAAACTTAGCATATAATCACGGGTTTAGAGGACGAGTCCCACCTT CT CTTGGTAAACTTCCGAAGCTCAGTAAGCTAGGTCTTGACACAAACAGTCTTGAAGCAAAT GA CAGCTGGGGCTGGGAATTCTTGGATGCATTGAGCAACTGCACTTCTCTAGAGATGCTTTC AC TCTATGCAAATCGGCTACAAGGAAACTTGCCAAATTCTGTTGGCAACCTTTCGTCTAATG TT AACAACCTCGTGTTTGGTAGGAATATGCTATATGGATTAGTTCCGTCAAGCATAGGAAAT CT CCATAGACTAACTAAGCTAGGACTGGAGGAGAACAGTTTGACTGGTCCGATTGATGGATG GG TTGGAAATCTTGCTAATTTGCAAGGTTTATATCTTCAACAGAACAATTTCACCGGGCAGA TT CCAACTTCCATTGGCAATAACTCCAAGCTGTCAGAACTGTTTCTGGCAAATAATCAATTC CA CGGTCCCATTCCATCAAGTTTCGAAAACCTTCAGCAACTCTTGTATTTAGACCTCAGCTA TA ACAATCTTCAAGAAAATATACCAAAAGAGCTTTTTAGTATAGCCACAATTGCCCAATGTG CG CTATCCCACAACAGTCTAGAAGGCCAAATTCCTCACATCAGTAATCTTCAACAACTCAAC TA TCTAGATCTTTCATCCAACAAGCTTACAGGGGAAATTCCACCTACTTTGCGCACATGCCA GC AATCGCAAGCCATCAAATTGGACCGGAACTTCCTCTCGGGAAGCATTCCCATGTTTCTAG GG AGTCTGAACAGCTTGATCGAGCTCAACCTTTCACATAACAATCTCTCAGGCTCTATCCCA AT TGCTCTAAGCAAACTGCAACTTCTCACCCAGTTGGATCTATCCGACAATCATCTTGAAGG AG AAGTACCAGTAGAAGGAATATTCAAAAATACAACAGCCATTTCCCTGAAAGGCAATTGGC GG CTTTGTGGAGGTGTGCTGGACCTACATATGCCTTCATGCCCCGCTGCTTCTCATAGAAGA TC TAGATGGCAATACTATTTGGTGAGAGTATTGGTCCCTATATTAGGCATCTTGTTACTCAT AT TAGTAGTCTGCTTATCCCTTCTCAGAAAGAGGATGCTGAGGATGCAGTTATCGTTGCCTT CT TCCGATGAGCAATTCCCTAAAGTATCTTATAAGGATCTACCACAGGCTACTGAGAACTTC AC AGTATATAACTTGATTGGGAGAGGAAGCTGCGGTTCAGTGTACAGAGCAAAGCTAAACCA AA AACAGATGGTTGTGGCAGTGAAAGTTTTTGACCTTGACATGCAAGGCGCGGATAAAAGTT TC ATCTCAGAATGTAAAGCACTGAGAAACATTCGGCACCGTAATCTTCTTCCAATTCTGACT GC ATGCTCAACAATTGATAACCAAGGCCGGGATTTCAAAGCTCTAGTCTACCAGTTCATGCC CA ACGGCAACCTGGACACTTGGCTGCACCCGGCAGGAGATGGAAAAGCCCCAAAGCAACTGG AC CTCTCTCAAAGAATGAAAATAGCTGTTGATATAGCCGATGCATTGCAATATATACACCAT GA CTGTGAGAATCCTATTGTTCACTGTGATTTGAAGCCCAGCAATATCCTCCTAGATTATGA TA TGACAGCTCGTTTGGGGGACTTTGGCATCGCAAGGTTGTACATCAAATCCAAATCAGCGG CA GCTGGAGGTTCGAGTTCAATGGGTACAATAACTCTGAGGGGCACGATTGGATATATTGCT CC AGAGTATGCGGGAGGTGGCTACCTATCGACGTCTGGAGACGCGTACAGTTTTGGGATAGT GC TGCTGGAGATGCTGACAGGAAGAAGGCCGACCGACCCTATGTTCTGCGAGGGGCTTGACA TC GTGAACTTTGTCAAGAGGAACTTTCCGGATCAGATACTTGATATCCTTGACGCTTCTCTC CG AGAAGAATGTCAAGACTGTTCTCAGGATAATCTGGAAGGAGAAAACGAAGTCCACCGGTG CC TGCTGTCCTTGCTGAAAGTGGCACTTTCTTGCGCAAGCCAGGATCCTAACGAACGAATGA AC ATGAGAGAAGCAGCTACTGAATTGCACGCGATCGACACATTGTATGTGTCTTGA

SEQUENCE ID NO.7 is as follows:

TRIAE_CS42_2BL_TGACv1_132242_AA0436300.1

ATGTCTGTGACGAGACTCAGCATGGTTAATCTGCTGGCGTTTTTGCTGCTGCTGTTC TATGG AGCTGGCAACATCAATTGCTCAACAGTCAATCACGAGAACAGTAGAGACATGCGCTCGTT GC TGGATTTCAAAGCGGCTACCAACGACCCAACAGATGCCTTGAGATCCTGGGACAGAAGCG TC CACTACTGCAACTGGACGGGTGTCATTTGCAGCTCATTGTGTCCAGGGCGTGTCGCCGCT CT GCAACTCGCCGGCCAAAGCTTGTCTGGCGAGATCACCCCCTCTCTTGGGAACTTAACGTT CC TTAAGGTCCTCAACTTGTCCTCCAATGGCTTCTCAGGCCAGTTAACTCCCCTAAACCTAA AC CAACTCCATGAGCTGGTCCTCCTTGACCTCAGCTCCAATTCATTCCAGGGGACGATTCCT GA CTCACTCATGAATTGTTCAAAACTACAGTATCTAGTTCTTTCTGGAAACATGCTAGAAGG TC CAATCCCCAAGAAAATTGGTTCTCTTTATAATCTATTAGGCTTAGGCCTTTCTAGGAATA AT CTTATTGGGGTCATCCCACTAACCATCAGCAACTCCACCCAGTTAGAACAACTTAGCCTT GA AGAAAATCAACTAGGGGGGAGCATTCCTGATGTGTTTGGGCAATGGTCCAAGATGTTGGA AT TGTCCGTAGGTGAAAATAGGCTCTCAGGTCGAATACCACCTTCAATCTTTAATCTGACTT CG CTTCAAATATTAGATTTGTATGCAAATAAGCTACAAGGGGAATTGCTGCTTGACATTGGC GA TACCCTCCCTGAAATCATAATTTTTACGCTGGGCCAGAACATTCTTGAAGGTCACATCCC AG CTTCCCTAGGAAACGCTTCACGGCTGCAAGTGATAGATTTGTCTTCTAACAGTTTCGTTG GA GAAATTCCTACTTTCGGAAAGCTACTAAACCTTATGAACATGAACCTTGGATATAATATG CT TGAATCAAGTGAAAGCCAAAGATGGGAATCCTTGTATGGACTAACAAACTGTAGTAATCT AT ATGCGCTAACATTAGATAGTAATCAGCTGCAAGGAGCCATACCAGATTTGGTCGGTAGGT TA TCCACTAAACTCAGACGTCTACACATGGGTGGAAACAATCTGTCGGGAATAGTTCCTTTA AG CCTAGCAAACCTTAGTAGCATAATCGATTTGGATCTTAGCAACAACAATTTAACTGGTAC AG TCGAAGGATGGTTAGGGAGTCTCAAAAACTTACAATCTTTAGATCTTCATGGAAATAATT TC ATTGGATCCATTCCACCATCTTTTGGCAACCTTTCAGAACTGACAATACTTTCTTTAGCA CA AAATGAATTTAAAGGTCACATACCTCCCACATTAGGAAAACTTTCACAACTCTCAAGGCT GG ACCTTAGCTATAATAATCTGCAAGGTGACATACCTCCAGAAATTAGTGAGCTTAAACAAC TC ATTGCACTATACCTCTCTTCTAGCAGACTCTCGGGAAAAATTCCTGATGATCTGGGCAAG TG TCAGGGCCTCGTAACCATCCAAATGGACCACAATAATCTCACGGGCGTCATTCCAACCTC TT TAGGCAACCTTTTGAGCTTGTACATGCTCAACCTGTCCTATAATGATTTATCAGGTGCCA TC CCAACAGTTCTAAGTGACCTTCAACTTCTTAGCAAGTTAGACCTATCATATAATCGTCTC CA AGGAGCACTCCCAAGAAATGGAGTGTTTGAGCACCCTGCAAACGTTTCACTTGATGGCAA CC AGGGACTTTGTGGACGGGCAACCGGTTTCCATGTGCCCTCATGCCCAGATGCCTCGCCGA GA ACAGGAAGACATTATCGTTTGCTTACGGTGTTGATCCCAATAATTGGCTTCCTGTCGCTG GC ACTGTTGACTTGCTTTATAATCCATGAGAAGATACCACAAGCAACGTTTTCATTGTTGCC TT CTCTTAGGGAGAAATTCCCTAGAGTTTCTTACTGGGATCTAGCTCGAGCGACAGGCAACT TC TCTGAGATTAACTTGATTGGCGAAGGAAGTTACAGTTCAGTGTACAAAGGAAAGTTGAGA CA AGTTAAAACGGAAATAGCAGTCAAGATACTTGACCTTGACATTCCAGGTGCCGAAGGAAG TT TTGCATTAGAATGCAAAGCGTTGAGAGGCATCCGTCACAGAAACATTGTTCCTCTCATAA CT GAATGCTCTGCAATCGACAACAAAGGCAATGCTTTCAGAGCTCTAATCTATGCTTTCATG CC CAATGGCAACTTGGATACTTGGTTGCATCATCAAGGGAATCAGGCAGCTGCAAGGCATTT AA GCTTAGCTCAAAGAATAAACATCGCTATTAACATAGCTGATGCATTGGACTATCTGCACC AT GATACTTGGAGGCCCATCATCCATTGTGATTTGAAGCCGAGTAACATACTCCTAGACATT CA TATGAATGCCTGTCTGGGAGACTTTGGCATCGCAAGGTTCTACATTGATTCTAAACTAAG AA CGGTCGGAGATTCAAGTTCAATTGCTGCAAACGGCACTCTGGGATATATGGCTCCAGAGT AT GCTGAAAGCGGTCATGCATCTACTTGTGGGGACGTATATAGTTTCGGAATAGTACTCTTG GA GATGCTGACAGGAAAAAGACCAACAGATCATATGTTCAGGAATGAACTCACCATTGTCAG AT TTGTGGAAACGAATTTTCCTGATCACATATTAAATTTTCTGGATTCCTGTCTGCTAGATG AA TGCAATGATGCCATCAACCAAGTAGCAGCAGGACTGGAAAATCCGGCAATCTTTCAGTCC TT GTTATCTTTGCTACGGATAGCACTTCTTTGTACACGCCAATCCCCAACTGAACGGCTTAA CA TGAGGGAAGTAGCTACCCAAATGCACAAAATCAACGTGGTGAACACGGGAGGGAGAGTGA GG AGCTCAACTTCTTTTAAGAGACTTGTCAGCTGGGCTTCTCAATGGAGCTAA

SEQUENCE ID NO.8 is as follows:

25 TRIAE_CS42_2DL_TGACv1_158196_AA0512090.2 ATGAAGCTCTTCGTGCTCATAGTATGGGCACTGTTGCTATTGTCTCATGGATCTGGAAGC GT CATTTGTGCTGTCCTCCATGGGAACGATACAGATATGCTGTCGCTTCTTGATTTCAAGCG CG CAATCACCGACGATCCAAAAGGGCTCTTGAGCTCATGGAACACCAGTGTTCACTTCTGCA AC TGGCAGGGTGTGAAGTGCAGCCTCGAAGAACATGAGCGCGTTGCAGAGCTGGACCTGTCG GA GCAGAGTTTTGTCGGGGAAATCTCTCCTTCCCTCGGAAACATGTCATATCTTACTTATCT TA ACCTTTCCAGAAGCAAGTTCTCTGGTCAGATACCACATCTTGGCCGGCTGCAAGAACTGG AG TTTCTTGACCTGAGTCACAACTCGCTACAAGGGATTATTCCAGTGACGCTCGCAAACTGC TC CAACTTGAGGGTGTTAGACCTCTCAAGAAACTTATTGGTGGGTGAAATTCCAGCAGAAAT AT CCCTACTCTCCAATCTGACACGCTTGTGGCTTTCTTATAATGATCTTACCGGGGTCATTC CA CCAGGCCTTGGCAATATCACTTCTCTAGAACATATTATTCTGATGTATAACCGGTTAGAG GG AGGCATTCCTGATGAGTTTGGGAAGTTGTCCAAAATGTCAAACTTACTCCTTGGTGAAAA CA AGCTATCAGGTAGAGTCCCAGAGGCCATTTTTAATATGTCTCTGCTAAATCAAATGGCAC TG GAGTTGAATATGCTAGTTGGTACTCTACCATCTAACATGGGTGATGCTCTCCCTAACCTC CG ACTTCTTACGTTGGGTGGTAACATGCTGGAAGGTCTTATCCCAGACTCATTAGGCAATGC AT CCGAGCTACAACTGATAAACTTAGCATATAATCATGGGTTTAGAGGACGGGTCCCACCTT CT CTTGGTAAACTCCCGAAGCTCCGTAAGCTAGGTCTTGACACAAACAGTCTTGAAGCAAAT GA CAGTTGGGGCTGGGAATTCTTGGATGCATTGAGCAACTGCACTTCTCTAGAGATGCTTTC AC TCTATGCAAATCGGCTACAAGGAAACTTGCCAAATTCTGTTGGCAACCTTTCGTCTAATG TT AACAACCTCGTGTTTGGTAGGAATATGCTATATGGATTAGTTCCATCAAGCATAGGAAAT CT CCATAGACTAACTAAGCTAGGACTGGAGGAGAACAAGTTGACTGGTCCGATTGATGGATG GA TTGGAAATCTTGCTAATTTACAAGGTTTATATCTTCAACAGAACAATTTCACTGGACAGA TT CCAACTTCCATTGGCAATAACTCCAAGCTGTCAGAACTGTTTCTGGCAAATAATCAATTC CA CGGTCCCATACCATCAAGTTTAGAAAACCTTCAGCAACTCTTGTATTTAGACCTCAGCTA TA ACAATCTTCAAGAAAATATACCCAAAGAGGTTTTTAGTGTAGCCACAATTGCCCAATGTG CG TTATCCCACAACAGCCTAGAAGGCCAAATTCCTCACATCAGTAATCTTCAACAACTCAAC TA TCTAGATCTTTCATCCAACAAGCTTACTGGGGAAATTCCACCTACTTTGCGCACATGCCA GC AATTGCAAGCCATCAAAATGGACCGGAACTTTCTCTCGGGAAGCATTCCCATATTTCTAG GC AGTCTGAACAGCTTGATCGAGCTCAGCCTTTCACATAACAATCTCTCAGGCTCTATCCCA AT TGCTCTAAGCAAACTGCAACTTCTCACCCAGTTGGATCTATCCGACAATCATCTTGAAGG AG AAGTACCAGTAGAAGGAATATTCAAAAATACAACAGCCATTTCCCTTAAAGGCAATTGGC GG CTTTGTGGAGGTGTACTGGACCTACATATGCCTTCATGCCCCGCTGCTTCTCAGAGAAGA TC TAGATGGCAACACTATTTGGTCAGAGTATTGGTCCCTATATTAGGCATCTTGTTACTCAT AT TAGTAGTCTGCTTAACCCTTCTCAGAAAGAGGATGCTGAGGATGCAGTTATCGCTGCCTT CT TCCGATGAGCAATTCCCTAAAGTATCTTATAAGGATCTAGCACAGGCTACTGGGAACTTC AC AGAGTCAAACTTGATTGGGAGAGGAAGCTGCGGTTCAGTGTACAGAGCAAAACTAAACCC AA AACAGATGCTTGTGGCAGTGAAAGTTTTTGACCTTGACATGCAAGGTGCGGATAAAAGTT TC ATCTCAGAATGTAAAGCGCTCAGAAATATTCGGCATCGGAATCTTCTTCCAATTCTAACT GC ATGCTCAACAATTGATAATCGAGGCAGGGATTTCAAAGCTCTAGTCTACCAGTTCATGCC CA ATGGCAACTTGGACACTTGGCTGCACCCGACAGGAGATGAAAAAGGCCCAAAACAATTGG AC CTCTCTCAAAGAATGAAAATAGCTCTTGATATAGCCGATGCATTGCAATATATACACCAT GA CTGTGAGAGCCCTATTGTTCACTGTGACTTGAAGCCCAGCAACATCCTCCTAGATTATGA TA TGACAGCTCGTTTGGGGGACTTCGGCATCGCAAGGTTCTACATCAAATCCAAGTCAGCAG CA GCTGGGGGTTTGAGTTCAATGGGTACAATGACTCTGAAGGGCACGATTGGATATATCGCT CC AGAGTATGCAGGAGGCAGCTACCTATCCACCTCCGGAGACGTGTACAGTTTTGGGATAGT AC TGCTGGAGATGCTGACAGGAAGAAGGCCGACCGACCCTATGTTCTGCGAGGGGCTTGACA TC GTGAACTTTGTCAGGAGGAACTTTCCGGATCAGATACTTCATATCCTTGACGCTTCTCTC CG GGAAGAATGCCAAGACTGCTCCCAGGATAATCTGGAAGAAGAGAACGAAGTCCACCGGTG CC TGTTGTCCTTGCTGAAAGTGGCACTTTCTTGCGCGAGCCAGGATCCTAACGAGCGAATCA AC ATGAGAGAAGCAGCTACTGAACTGCACGCGATCGACGCGTCGTTTGTGTCTTGA

SEQUENCE ID NO.9 is as follows:

TRIAE_CS42_6AL_TGACv1_471249_AA1505410.2

ATGCGTTCTCCCAAGCAACCGGCGAAGCTCGTCATGCTTTTACTGTTGGCACTGCTG CTGCT CTGTAACGGAGTTGGCAACGTCCATTGCACAAGGATCCACGAGAACAGCGTCGATCTGCA CG CGCTGCTAGACTTCAAGCAGGGCATCAACAATCCTCAGGAAGCCTTGAGCAATTGGAGCA CC ACCACCCACTTCTGTCGATGGAATGGTGTCATCTGCACCACGACACGGCCGTTTCGTGTC TT GTCGCTTATACTCACTGAATTGGACTTAGCAGGCCAAATCAGCTCCTCTCTTGGAAACTT AA CCTTCCTTGAAACGCTTGACCTTTCATATAATAACTTCGTTGGTCCCTTACCTGTCCTTG GC CATCTCCAACAACTCCAGACACTTTCTCTGAACAACAACAGGTTAAATGGGATGATTCCT GA TTCACTTACCAACTGTTCCAGCTTGGACACTTTAGATCTCTCTGTAAACTTCCTAGTGGG TC CAATTCCTCCGAATTTGGACTTGCTTTCAAATCTTACTTACTTAGATCTCTCTAGTAACA TG CTAGTGGGTCAAATTCCTCCGAAACTAGTTTCTCTATCAAAGCTGGTCACATTAGATCTC TC CCATAACATGCTAGTTGGTCCAATTCCTCCGAATCTGGACTTGCTTTCAAATCTGACTTA CT TAGATCTATCTAGAAACTTGCTAGTGGGTCAAATTCCTCTGAAAATAGTTTCTCTACCAA AG CTGGCCACATTAGATCTCTCTACTAACATGCTAGTGGGTCAAATTCCTCCGAAGTTAGGC TT TGTTTCAAGTCTAGAATACTTCAGTTTGGCATCAAACAAACTCGAGGGAAGCATTCCTAA TG AGCTTGGGCAATTGCCTAGTTTACAATACTTGCTCCTGGGAGAAAATAATCTTTCAGGTG AA TTCCCGCATTCCATCTTGAACAGAAACCTTTCTGTTTCTCTCCTATATCTAGGCTTGGAG CT GAATATGCTAGGCAAGGTATTGCCACCTAATATAGGTGACCTTCGGGGTCTCGTACACCT TA CAATGAGTGGCAACATGTTTGAAGGGCACATCCCAGCTTCCCTAGGCAACGCCACAGGAT TA AAAGTAATAGACTTATCAGCTAACAATTTCACCGGGCAAATTCCTAACTCTTTTGGAAAG CT CTCAAATCTGACTAATCTAAACCTTCAGTATAACCAGCTTGAAACAAGGGACTGGGAATT CT TCAATGCATTGACGAACTGTCGTTCTCTAAACTCACTCTCACTGGGTTTCAACCAGCTGC AG GGATCTATACCGCAGTCTGTCGGTAACCTATCCAACAAACTAGAAAAACTTACTTTGACT CA AAATAGCTTATCAGGACAAGTACCCCAGAGCATCGGCAACCTTAGTGCATTAAATCAACT GG CACTAGGTATAAACAACTTAAGCGGCACAATAGAAGGATGGATTGGAAACCTAAAAGGCC TT GAAGGATTAACTCTCCGCTCAAACCGCTTCACCGGCCAAATCCCACCCTCTATTAGCAAT CT TACTCGGTTGATAAATCTTTATCTCTATGATAATCAATTCGAGGGCCTCATACCCCCCAG CC TGGGAAACCTCCCACTCACACAGCTAGTCCTTAGCTCTAACAATCTTTACGGGTACATAC CA CCCAGCTTAGGAAGCCTCCAACAGCTTACGTCATTGAATCTTAGCCACAATAATCTCCAA GG TGAGATACCTCAGATTAGCGCCCTTAAGCAACTCACTACTTTAGATCTTTCTTCAAATAA GC TCACAGGGAGTATTCCAGATTCTTTGGGCCAATGTTACGGCTTACGGAGTCTGCAAATGG AC CAAAACTTTCTGTCAGGAAACATCCCAATAGCCTTTGGCAAACTGTTGTCTCTGAGTATA CT AAATCTATCACACAACAACTTGTCAGGCACCATCCCGTCGGCTCTAAACAAACTAGAGTT CC TAAACCATCTTGACCTTTCATATAATCATCTTGAAGGAAAAATACCCAGAGATGGAGCAT TC GAAAATGCTACGGCTGTTTCACTTGAGAACAATTGGGGGCTCTGCGGAGGCGCCGTGGAT CT TCACATGGCTTCATGCACAACCATTTCCAAGAAAGAAGAGGAGAGACGATACCGTTTGAT TA AAGTATTGATTCCAATATTTGGATTCTTGTCACTGGTACTGTTGATCTACTTTGTACTCC TT GAGAAGAAGATGCGAAGGGCAAATGATACATCAGCTTCATTAGGCGAGAATTTTCTGAAG GT TTCTTATGCGGATCTAGCACAAGCCACATCAAACTTCTCTGAATCTAACCTGGTTGGGAG AG GAGGTTATGGCTCTGTCTATCGCGGAAAGTTAAAGGATTCTAAGGTGGAAGTGGCCGTCA AG GTTTTTGATCTTGAAATGCATGGAGCTGAGAGAAGCTTTCTGAAAGAATGCGAGGCACTG CG AAGCATTCAGCATAGAAATCTTCTTCCCATCATAACTGCTTGCTCGACGGTAGACAATAC AG GCAATGTTTTCAAAGCTTTAGTTTATGAGTTCATGCCTAATGGGAACCTAGACACATGGC TG CATCACAGAGAGGACGGGAAGGCTCATAAACATTTAAGCTTAGCTCAAAGATTAGACATA GC TGTTAACATGGCTGACGCACTGGATTATCTACACCATGACTGCGGAAGACCCACCATCCA TT GTGACCTGAAGCCCAGCAACATTCTTCTGGATGATGATATGACCGCTCTTTTAGGAGACT TT GGTATTGCAAGTTTTTACCAAGATTCCAGGTCAACATCACCTGGTTCAGTGAGTTCATCA TC AGTCGGTATGAAGGGTACTATTGGATATATTGGTCCAGAGTACGCGGGAGGTGGCCGCCA TG CATCAACTTGCGGAGATGTTTACGGTTTTGGGATAATACTGCTGGAAATGATGACCGGAA AA AGACCAACAGATCCATTGTTCAAGGATGGAGTTAGCATTGTCGACTTTGTGGAGAGCAAC TT TCCACATGAAATAGTTCGTGTCATTGATGCTAATCTCAGTGAAGAATGCAAGGACATTGC TC AATCAAAGAAGATTTCAGAAAATTCAGTTCATCAATGTTTGCTATCTGTGCTGCAACTAG CA CTTTCCTGTACGCACCCAGTACCAGGCGAAAGAATGAATATGAAAGTGGTGGCCAGCAAA AT GCATGCAATTAAAACATCCTATGGGGGCTGCAATGCGCAAGAGTGA

SEQUENCE ID NO.10 is as follows:

TRIAE_CS42_6BS_TGACv1_514259_AA1657570.3

ATGATGGATCTCCACATGAAGTTTCTCCTGGCCTCCCTCAGCTGTGTACTTCTGATA CAAGG AGCTTTCTGTGGGGGGACTGGAGCGACAAGCTGGACTTGTGTGTGCACCGCTCATCCACT TG GCGAAGCAAACTCCAATAGCAGCCTGTCATCCAGTTGCGACTCCTCGTGCCATTGCATAC GA GATGAAAACGGCGGCACAGGGTCATGGAACTGCTCGTGCCGCTCCGACAAGGACCTTCAG GA AGAAGAACACGCTGTGGTGCACAGTGGGAGTTGCTTCACTTCCTGTAACTGCACATCTGG AA GTTCTGAACAAGAGAGGAAGCATTTCTCTAGCAAAACAGTCATTGCTACACTCCTGGTAT GT GTGGTTCTCACCACTGTTGCTTTCGTCGGAACAACGGCGTACTACTTCCGCCGCAAGGAC GC ACTCTCCCCGCGTTCCCGGATGCACTCTTTCGACAAGTACGCGAGCTGGAGCAGCAGATC GA ACCTCGTTAGCCATCGATCTTCTCCCCTTACCCAACTGAAACCCAAACCCGGGCTCAGTG TC ATCAAAGGGTTTTTGTGTAGCTGCCCACTCGTCTCCCGGAGCGAAGACGGCCCATTCCCC GG CGTGGTTCTCCGGTTCTCCTACGTCGAGCTGGAGCAGGCAACAGGGAAATTTTCCGACGA AC ACCTCATCGGCGTCGGCGGGACCAGCAAGGTGTACCGTGGACAGCTCGCCGACGGCAAAG TC GTCGCCGTGAAGAAGCTTCGGCCCCTCGGTGGTGCGGACGAAGACTATGAGTTCCTGTCA GA GATCGAGCTGCTGTCACGGCTGAACCACTGCCATGTGGTGCCATTGCTGGGGTACTGCTC GG AGCGGCAGGGGCGGCAGCTGGAGCGGCTGCTGGTGTTCGAGTGCATGACCAACGGCAACC TG CGGGAGTGCCTGGACGACCTCAACAGGAAGCCCATGGACTGGGCGACGCGCGTCGGCGTG GC GCTGGGCGCCGCGAGGGGCCTCGAGTACCTCCACGAGGCGGCGGCGCCGCGCATCCTCCA CC GCGACATCAAGTCCACCAACATCCTGCTCGACGACCGGTTCAGGGCCCGGATCACGGACC TG GGCATGGCCAAGTGCCTGATGAACGACGGCGTGACGAGCTGCTCTAGCTCGCCGGCGCGG AT GCTGGGCACCTTCGGGTACTTCGCCCCCGAGTACGCCATCGTCGGCAAGGCGTCGCTCAA GT CGGACGTCTTCAGCTTCGGCGTGGTGGTGCTCGAGCTCATCACCGGCCGGCAGCCGGTGC AC AAGAGAGGCGGCGCCGGCGCCGGTGGCGGCGGCACGGACGAGAGCCTGGTGATGTGGGCG AC GTCGCGGCTCCGGGACAGCAGGTTGGTGGTGGCGGAGCTGCCGGACCCGGCGCTGAAGGG CG CGTTCCCGCCCGAGGAAATGCAGATCATGGCGCACCTGGCCAGAGAGTGCCTGCAGTGGG AC CCCGAGGCCAGGCCCACCATGACCGAGGTCGTTCAGATCCTCTCCACCATCGCGCCCCTT GC CGACAAGCGCCGTCGCCACCACCTGCCCGCCGCCGCCGCCGCCTTCGCCCCGGGCTTCCG TG CCGAGAAGCCGCAGGAATGCTCAGTGTGGCAGGACGGCGACGACGGCCGTCGCCGTGATC AC CTGCACGGGGGGAACGGTAGCAATGCAAAGGGCACCGTCTTGTCGGGCGAGGTCGCGGTT AA CGTCGGCACGCCGGCGGCGATGGGCCGGAGCTGGCGGTCGGCGGAGCAGGAGGAGGTGGA CC TGACGGAGCCGCGGCTGGAGACGTTCACGCAGCCGACAACGACGGCGAGCCTCTTCAGGT GA

A variant of SEQ ID NO. 2 is also provided.

Typically, the variant has at least about 30%, 40%, 50%, 60% or 70% sequence identity with SEQUENCE ID NO. 2.

In a preferred embodiment, the variant has at least about 70% sequence identity with SEQUENCE ID NO. 2. Preferably, the variant comprises (or consists of) a sequence having at least about 70, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94,

95, 96, 97, 98 or 99% sequence identity with SEQUENCE ID NO. 2. Typically, the variant has from about 74% to about 89% sequence identity with SEQUENCE ID NO. 2. Typically, the variant is a functional variant.

In an embodiment, the variant may have a sequence comprising (or consisting of) SEQUENCE ID NO. 1 1 , SEQUENCE ID NO. 12 or SEQUENCE ID NO. 13.

SEQUENCE ID NO. 1 1 is as follows: MSDQSVKLNMLLLLAFLLLSYGAGNARCSTVHANITDILSLLRFKRSTHDPTGSLRNWNR SI HYCKWNGVSCSLLNPGRVAALDLPGQNLSGQVNPSLGNITFLKRLNLSSNGFSGQLPPLS QL HELTLLDMSSNLFQGI IPDSLTQFSNLQLLNLSYNGFSGQLPPLNQLPELVVLDLKSNLFQG I IPDSLTNCSNLTFVDLSRNMLEGS IPAKIGSLYNLMNLDLSRNKLTGVIPPTI SNATKLQF LILQENELEGS IPSELGQLSNMIGFTVGSNRLSGQIPAS IFNLTLLRVLGLYANRLQMAALP LDIGHTLPNLQNITLGQNMLEGPIPASLGNI SSLQLIELSNNSFTGEIPSFGKLQKLVYLNL ADNKLESSDSQRWESLYGLTNCSHLKSLRFKNNQLKGVIPNSVGKLSPKLELLHLGGNNL SG IVPSSIGNLDGLIDLDLSTNSFNGTIEGWVGSLKKLQSLDLHGNNFVGAIPPSFGNLTEL TY LYLAKNEFEGTIPPILGKLKRLSAMDLSYNNLQGDIPPELSGLTQLRTLNLSSNRLTGEI PV DLSQCQDLVTIQMDHNNLTGDIPTTFGDLMSLNMLSLSYNDLSGAIPVSLQHVSKLDLSH NH LQGEIPPEGVFRNASAVSLAGNSELCGGVSELHMPPCPVASQRTKIRYYLIRVLIPLFGF MS LLLLVYFLVLERKMRRTRYESQAPLGEHFPKVSYNDLVEATKNFSESNLLGKGSYGTVYK GN LVQHKLEVAVKVFNLEMQGAERSFMPECEALRSVQHRNLVS I ITACSTVDSDGRAFRALIYE FMPKGNLDTCLHHKGDGKADKHLTLTQRIGIAV IADALDYLHNDSENPI IHCDLKPS ILL DEDMVAHLGDFGIARIFLDSGLRPASSTSS IGVKGTIGYIPPEYGGGGRI STSGDVYSFGIV LLEMLTGKRPTDPMFMDGLDIVNFVGNKFPHQIHEVIDIYLKGECESEDSVHQCLVSLLQ VA VSCTHS IPGERA IRDTASKLQEIKASYLGRKAKINPSV SEQUENCE ID NO. 12 is as follows:

MSDQSVKLNMLLLLAFLLLSYGAGNARCSTVHANITDILSLLRFKRSTHDPTGSLRN WNRSI HYCKWNGVSCSLLNPGRVAALDLPGQNLSGQVNPSLGNITFLKRLNLSSNGFSGQLPDAS QH ELLLIPRDNPRFTHTIFEPTAPEFVLQWLLRPVTSSEPASRAGGSQLEIQFIPRDNPRLT HK LFEPHVCGSFKKHARRLNPGENRFALQSNEFRPFNEMTHRGHTTNHQPMPPSYNFSFFKK MH LEGKHTQLAWTIVQHDSALLVGSNKALRSNAQHAIFKSYFGSKCLGWYANKTTKWRALPI RI GPNPPLI SKKLTLGPKKAMKVLSQRRSVTFQACNLQSYPITVSLEKFLVSESYRNLYTYTLR TI SWSQVTAKDGNLYMDQQTAVIHNRSDSRI I SQKESYQIRSVNCPLNLNFYIWGGNNLSGI VPSSSGNLDGLIDLDLSTNSFNGTIEGWVGSLKKLQSLDLHGNNFVGAIPPSFGNLTELT YL YLAKNEFEGTIPPILGKLKRLSAMDLSYNNLQGDIPPELSGLTQLRTLNLSSNRLTGEIP VD LSQCQDLVTIQMDHNNLTGDIPTTFGDLMSLNMLSLSYNDLSGAIPVSLQHVSKLDLSHN HL QGEIPPEGVFRNASAVSLAGNSELCGGVSELHMPPCPVASQRTKIRYYLIRVLIPLFGFM SL LLLVYFLVLERKMRRTRYESQAPLGEHFPKVSYNDLVEATKNFSESNLLGKGSYGTVYKG NL VQHKLEVAVKVFNLEMQGAERSFMPECEALRSVQHRNLVS I ITACSTVDSDGRAFRALIYEF MPKGNLDTCLHHKGDGKADKHLTLTQRIGIAV IADALDYLHNDSENPI IHCDLKPS ILLD EDMVAHLGDFGIARIFLDSGLRPASSTSS IGVKGTIGYIPPEYGGGGRI STSGDVYSFGIVL LEMLTGKRPTDPMFMDGLDIVNFVGNKFPHQIHEVIDIYLKGECESEDSVHQCLVSLLQV AV SCTHS IPGERANIRDTASKLQKKVVNCPL

SEQUENCE ID NO. 13 is as follows:

MSDQSVKLNMLLLLAFLLLSYGAGNARCSTVHANITDILSLLRFKRSTHDPTGSLRN WNRSI HYCKWNGVSCSLLNPGRVAALDLPGQNLSGQVNPSLGNITFLKRLNLSSNGFSGQLPPLS QL HELTLLDMSSNLFQGI IPDSLTQFSNLQLLNLSYNGFSGQLPPLNQLPELVVLDLKSNLFQG I IPDSLTNCSNLTFVDLSRNMLEGS IPAKIGSLYNLMNLDLSRNKLTGVIPPTI SNATKLQF LILQENELEGS IPSELGQLSNMIGFTVGSNRLSGQIPAS IFNLTLLRVLGLYANRLQMAALP LDIGHTLPNLQNITLGQNMLEGPIPASLGNI SSLQLIELSNNSFTGEIPSFGKLQKLVYLNL ADNKLESSDSQRWESLYGLTNCSHLKSLRFKNNQLKGVIPNSVGKLSPKLELLHLGGNNL SG IVPSS IGNLDGLIDLDLSTNSFNGTIEGWVGSLKKLQSLDLHGNNFVGAIPPSFGNLTELTY LYLAKNEFEGTIPPILGKLKRLSAMDLSYNNLQGDIPPELSGLTQLRTLNLSSNRLTGEI PV DLSQCQDLVTIQMDHNNLTGDIPTTFGDLMSLNMLSLSYNDLSGAIPVSLQHVSKLDLSH NH LQGEIPPEGVFRNASAVSLAGNSELCGGVSELHMPPCPVASQRTKIRYYLIRVLIPLFGF MS LLLLVYFLVLERKMRRTRYESQAPLGEHFPKVSYNDLVEATKNFSESNLLGKGSYGTVYK GN LVQHKLEVAVKVFNLEMQGAERSFMPECEALRSVQHRNLVS I ITACSTVDSDGRAFRALIYE FMPKGNLDTCLHHKGDGKADKHLTLTQRIGIAV IADALDYLHNDSENPI IHCDLKPS ILL DEDMVAHLGDFGIARIFLDSGLRPASSTSS IGVKGTIGYIPPEYGGGGRI STSGDVYSFGIV LLEMLTGKRPTDPMFMDGLDIVNFVGNKFPHQIHEVIDIYLKGECESEDSVHQCLVSLLQ VA VSCTHS IPGERA IRDTASKLQEIKASYLGRKAKINPSV

In an embodiment of the invention, a fragment of SEQUENCE ID N0.1 is provided. The fragment is a functional fragment of SEQUENCE ID NO. 1 . In an embodiment, the fragment has from 10 to 3000 contiguous nucleotides preferably about 100, 250, 500, 750, 1000, 1250,1500, 1750, 2000, 2250, 2500 or 2750 nucleotides.

In an embodiment of the invention, a fragment of SEQUENCE ID NO.2 is provided. The fragment is a functional fragment of SEQUENCE ID NO. 2. In an embodiment, the fragment has from about 10 to 1000 contiguous amino acids, preferably about 50, 100, 5 200, 300, 400, 500, 600, 700, 800, or 900 amino acids.

The current invention provides a construct comprising a nucleotide sequence of SEQUENCE ID NO. 1 or a variant thereof or fragment described herein.

The construct may be an expression vector. The vector may comprise regulatory machinery, for example promoters, terminators, and/or enhancers. The nucleotide may be under the control of a promotor region. The promotor may be a constitutive plant cell specific promotor. It will be appreciated that any suitable plant cell specific promotor known in the art may be used. The promotor may be such that multiple copies of Tal_RRK-6D are produced. In an embodiment, the vector is a virus, such as a bacteriophage and comprises, in addition to the nucleic acid sequence of the invention, nucleic acid sequences for replication of the bacteriophage, such as structural proteins, promoters, transcription activators and the like.

In an embodiment of the invention, the construct of the invention and described herein may be used to transform plant host cells to produce a recombinant cell in order to express Tal_RRK-6D or synthesize the protein. This imparts or enhances FHB resistance in the plant.

In a further embodiment, a recombinant host cell comprising a construct as described herein is also provided by the current invention. The host cell may be any biological plant cell which can be cultured in medium and used for the expression of a recombinant gene. The invention also provides a transformation platform comprising a recombinant construct of the invention. Typically, the transformation platform comprises a bacterium capable of mediating cellular transformation.

The invention also provides plant material genetically transformed or modified with a nucleotide, recombinant construct or transformation platform of the invention. In an embodiment, the transformed plant material comprises a transformed cell capable of overexpression of Tal_RRK-6D or a variant thereof. In other words, the host cell overexpresses Tal_RRK-6D or a variant thereof compared to unmodified host cell.

The plant material may be a transgenic plant. The transgenic plant is resistant or has enhanced resistance (compared to a non-transgenic plant) to FHB.

Typically, the plant material comprises a plant cell carrying a transgene, in which the transgene comprises the nucleotide of the invention.

In the current invention, the plant material is selected from but not limited to a plant cell, plant cell culture, plant tissue, plant, or seed for a plant. It will be understood that any suitable plant material known in the art may be used.

In the current invention, the plant is a cereal. Typically, said cereal is selected from but not limited to the group comprising maize, rice, wheat, barley, sorghum, millet, oats, soybean and rye. Preferably, the cereal is wheat.

The invention also provides a method of genetically transforming a plant material comprising the steps transforming a cell or cells of the plant material with a nucleotide, recombinant construct or transformation platform of the invention. The transformed cell may be capable of overexpression of a nucleotide of the invention. In other words, the host cell overexpresses Tal_RRK-6D compared to unmodified host cell.

The invention also provides a method of producing a transgenic plant comprising the steps of transforming a plant material according to a method of the invention as described herein and generating or growing a transformed plant from the transformed cell.

The invention also provides a method of producing a plant material having resistance to FHB disease, the method comprising the steps of transforming a plant material with a construct of the invention or a transformation platform according to the invention, and optionally growing the plant material. Preferably, the recombinant construct comprises SEQUENCE ID NO: 1 or a variant thereof. In this manner, a plant which is resistant to FHB may be produced. Typically, the plant shows reduced or an absence of FHB symptoms when infected with Fusarium fungus compared to a non-transgenic plant. The plant or plant material transformed with the construct or transformation platform of the invention may already express endogenous Tal_RRK-6D. This may be at a low level. Host cells are transformed using techniques known in the art such as, but not limited to, electroporation; calcium phosphate base methods; a biolistic technique or by use of a viral vector. After transfection, the nucleotide of the invention is transcribed as necessary and translated. In some embodiments, the synthesized protein is allowed to remain in the host cell and cultures of the recombinant host cell are subsequently used.

The current invention also provides a functional marker for FHB resistance. The marker is the Tal_RRK-6D. The marker may be the nucleotide or the peptide of the invention. This provides ways to develop FHB wheat cultivars by marker assisted selection and breeding. A method of determining FHB resistance or a method of selecting FHB wheat cultivar, by detecting or measuring Tal_RRK-6D expression levels, and optionally growing the FHB wheat cultivar, is also provided.

In another embodiment, the Tal_RRK-6D also functions as a selectable marker gene, wherein the traits displayed by the transformed cell function as a selective marker for the successful incorporation of the transgene. It will be appreciated that incorporation of the transgene may be by any method as described herein. A method of using Tal_RRK-6D as a selectable marker is provided. The traits may be those of FHB resistance.

The marker may be the nucleotide sequence of the invention or the amino acid sequence of the invention.

Also provided is plant material genetically transformed according to a method of the invention.

A further aspect of the invention provides an isolated sequence comprising (or consisting of) SEQUENCE ID NO. 1 or a functional variant thereof or a functional fragment thereof.

Preferably, the variant has at least 55% sequence identity with SEQUENCE ID No. 1 . Preferably, the variant has at least 60% or 70% sequence identity with SEQUENCE ID NO. 1 .

In a preferred embodiment, the variant has at least about 70%, 75%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO. 1 , typically between about 91 .5 % to about 95% sequence identity with SEQUENCE ID NO. 1 A further aspect of the invention provides an isolated peptide comprising (or consisting of) SEQUENCE ID NO. 2 or a functional variant thereof or a functional fragment thereof. The invention also provides an isolated protein encoded by the nucleotide of the invention or having a sequence of SEQUENCE ID NO. 2 or a functional variant thereof or a functional variant thereof.

Typically, the variant has at least about 30%, 40%, 50%, 60% or 70% sequence identity to SEQUENCE ID NO. 2.

In a preferred embodiment, the variant has at least about 70% sequence identity to SEQUENCE ID NO. 2. Preferably, the variant comprises (or consists of) a sequence having at least about 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 30 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with SEQUENCE ID NO. 2. Typically, the variant has between about 74% to 89% sequence identity with SEQUENCE ID NO. 2.

EXAMPLES

Example 1

Tal_RRK-6D gene expression in wheat heads Study Description

To confirm that TaLRRK-6D homologue specifically was responsive to the fungus Fusarium, a quantitative RT-PCR assay was used to measure the level of gene expression in wheat heads treated with the fungus.

Strains The deoxynivalenol producer Fusarium graminearum (strain GZ3639) was used in this study. Method

Spikelets were inoculated with the deoxynivalenol producer Fusarium graminearum (strain GZ3639). Expression levels were tested up to 7 days (at day 1 , 2, 3, 5 and 7) post fungal inoculation. The effect of the DON-non-producing mutant derivative of GZ3639, namely GZT40, on TaLRRK-6D expression was also analysed. The effect of TaLRRK-6D in wheat heads treated with mycotoxin DON was also analysed.

Results

The results showed that the TaLRRK-6D expression was early induced at 1 day post inoculation (dpi); with a peak of induction at 2 dpi, followed by a return to a basic level. This is illustrated by Figure 3. The induction of TaLRRK-6D expression by GZT40 was very low at all the days post inoculation (Figure 3). The expression results for TaLRRK-6D in wheat heads treated with mycotoxin DON, showed significant increase of TaLRRK-6D transcript accumulation in response to the toxin. This was maximal at 1 dpi, and gradually reduced in the next few days (Figure 3). From these results, it is evident that TaLRRK-6D is responsive to FHB and it is concluded that TaLRRK-6D is a component of the early host response to Fusarium fungi.

Example 2

Tal_RRK-6D role in resistance to FHB

Study Description The virus-induced gene silencing (VIGS) platform was used to validate TaLRRK-6D role in resistance to FHB in two wheat cultivars - the FHB resistant cv. CM82036 and the susceptible cv. Remus.

Strains

Wheat resistant cv. CM82036 and susceptible cv. Remus. Methodology

Virus induced gene silencing:Two independent constructs were designed (BSMV:LRR1 and BSMV:LRR2) which target two distinct sequences of the TaLRR gene (Figure 5). Plants comprising an empty vector (BSMV-00) which serves as a positive control and plants in which no construct was incorporated (negative control) were also included in the experiment. Figure 6 is a pictorial representation of the two VIGS construct for its specificity to TaLRRK-6D. Constructs were applied to the flag leaves of the wheat cv. CM82036 and cv. Remus before emergence of the primary head. Two weeks later, two central spikelets were treated with FHB (16.9 mM) or mock 0.02% Tween20 treatment at mid anthesis (growth stage Zadoks 65). The phenotypic effect of FHB on plants at 7 and 14 days post-FHB treatment was also analysed by measuring the number of spikelets with FHB symptoms, e.g. discolouration.

Results

At 1 dpi, one spikelet above the one which had been treated was removed and used to measure the expression level of TaLRRK-6D by quantitative RT-PCR. Very low TaLRRK-6D expression was observed in the non-toxin treated plants (;mockTween treated), whether in the controls (FES),(BSMV:00) or silenced plants (BSMV:LRR1 and BSMV:LRR2) (Figure 7).

In both cultivars, silencing reduced Tal_RR-6D expression for both mock (no GZ3639) and Fusarium (GZ3639) treated samples (comparing BSMV:LRR 1 and BSMV:LRR2 versus BSMV:00). Silencing of TaLRRK-6D due to BSMV: LRR1 and BSMV: LRR2 plants treatment increased the FHB severity by 54.5% and 72.7% (as compared to mock and BSMV:00-treated plants) as illustrated in Figure 8.

Plants treated with BSMV:LRR1 and BSMV:LRR2 were significantly more sensitive to FHB induced damage of spikelets than the non-silenced plants BSMV:00 (6.5 and 7.3 fold increase), as illustrated by Figure 9. The TaLRRK-6D silenced spikelets showing FHB-induced damage was significantly reflected in yield reduction as compared to the BSMV:00 treatment (Fig. 10). This indicates a direct role of TaLRRK-6D in FHB resistance in wheat plants.

Example 3 Role of Tal_RRK-6D in FHB in barley

Study Description

In order to understand the role of TaLRRK-6D in Fusarium head blight in barley, wild type barley cv. Akashinriki lines were used.

Methodology VIGS were used to silence LRR-RLK homolog in barley at 2nd leaf stage. Using detached leaf assay described by (Browne & Cooke, 2004), the effect of TaLRRK-6D silencing on the barley in response to F. culmorum strain FC200 was assessed. Leaves were point-inoculated with fungal conidia in the wild type cv. Akashinriki and the diseased leaf area monitored at 4 dai.

Results The lines silenced with BSMV:LRR1 and BSMV:LRR2 developed severe lesions, and increased disease symptoms of 2.24 and 3 folds compared to BSMV:00 were observed (P<0.05) for Akashinriki silenced lines with construct BSMV:LRR1 and BSMV:LRR2 respectively as illustrated by Figure 1 1 . The number of conidia developed on the leaves at 4 dai was also determined and all two BSMV:LRR1 and BSMV:LRR2 silenced lines contained 20 224% and 293% more conidia than the wild type cv. Akashinriki that was treated with BSMV:00 was statistically significant (P<0.05) as illustrated by Figure 12. The diseased leaf area monitored at 4 dai was found to be 5.8 cm2. Thus, the detached leaf results show that silencing of TaLRRK-6D leads to enhanced wheat leaf susceptibility to F. colmorum strain FC200.